- Home
- ADAG vs KPTI Comparison
ADAG vs KPTI Comparison
Compare ADAG & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADAG | KPTI |
|---|---|---|
| Founded | 2011 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.3M | 172.6M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | ADAG | KPTI |
|---|---|---|
| Price | $3.60 | $7.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $8.00 | ★ $17.50 |
| AVG Volume (30 Days) | 211.2K | ★ 603.2K |
| Earning Date | 03-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | $3,688.61 | N/A |
| Revenue Next Year | $17.39 | $46.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $1.33 | $3.51 |
| 52 Week High | $4.58 | $10.99 |
Technical Indicators
Market Signals| Indicator | ADAG | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 56.38 | 40.32 |
| Support Level | $1.69 | $7.15 |
| Resistance Level | $4.58 | $7.81 |
| Average True Range (ATR) | 0.43 | 0.79 |
| MACD | 0.02 | -0.21 |
| Stochastic Oscillator | 42.72 | 7.83 |
Price Performance
Historical ComparisonAbout ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).